<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; AmerisourceBergen Corporation</title>
	<atom:link href="http://www.stockbloghub.com/tag/amerisourcebergen-corporation/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Sun, 20 May 2012 20:27:31 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(ABC) AmerisourceBergen Posts Modest Second Quarter Results</title>
		<link>http://www.stockbloghub.com/2012/04/30/abc-amerisourcebergen-posts-modest-second-quarter-results/99760</link>
		<comments>http://www.stockbloghub.com/2012/04/30/abc-amerisourcebergen-posts-modest-second-quarter-results/99760#comments</comments>
		<pubDate>Mon, 30 Apr 2012 18:00:50 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health Inc.]]></category>
		<category><![CDATA[ESRX]]></category>
		<category><![CDATA[Express Scripts Inc.]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=99760</guid>
		<description><![CDATA[AmerisourceBergen Corporation (ABC) posted second quarter fiscal 2012 earnings of 81 cents per share, in line with the Zacks Consensus Estimate. However, earnings increased 5.2% from the year-ago period, spurred by higher revenues and a lower share count. Revenues Total revenue for the second quarter edged up 1.6% to $20.1 billion, which were also in line with the Zacks Consensus Estimate. The modest advance in revenues was the result of a 6% increase in AmerisourceBergen Specialty Group’s revenue. The revenue increase for the AmerisourceBergen Specialty Group segment was driven by growth in third party logistics and vaccine and physician office distribution business. The robust performance of AmerisourceBergen Drug Corporation’s institutional segment was offset by the loss of a significant retail customer. TheraCom, a recent acquisition, also contributed toward the quarter’s ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/30/abc-amerisourcebergen-posts-modest-second-quarter-results/99760/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Analyst Maintains Outperform on Shares</title>
		<link>http://www.stockbloghub.com/2011/12/07/cah-cardinal-health-analyst-maintains-outperform-on-shares/88134</link>
		<comments>http://www.stockbloghub.com/2011/12/07/cah-cardinal-health-analyst-maintains-outperform-on-shares/88134#comments</comments>
		<pubDate>Wed, 07 Dec 2011 17:53:10 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health Inc.]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88134</guid>
		<description><![CDATA[We reiterate our Outperform rating on Cardinal Health (CAH). Its first-quarter fiscal 2012 (ended September 30) adjusted earnings per share of 73 cents beat the Zacks Consensus Estimate of 72 cents. Earnings from continuing operations (as reported) dropped about 19% year over year reflecting a previous-year gain from the sale of CareFusion (CFN) shares. Sales for the first quarter rose 10% year over year to $26.8 billion, exceeding the Zacks Consensus Estimate of $26.3 billion. Sales were boosted by growth across the board, notably, buoyancy in the larger Pharmaceutical segment. Revenues from the Pharmaceutical segment spiked 10% year over year in the quarter. Acquisitions contributed to growth as did organic growth from pre-existing clients. Sales from the smaller Medical segment climbed 10%, driven by higher sales to existing and net ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/07/cah-cardinal-health-analyst-maintains-outperform-on-shares/88134/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABC) AmerisourceBergen Analyst Reiterates Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2011/08/26/abc-amerisourcebergen-analyst-reiterates-neutral-on-shares/82113</link>
		<comments>http://www.stockbloghub.com/2011/08/26/abc-amerisourcebergen-analyst-reiterates-neutral-on-shares/82113#comments</comments>
		<pubDate>Fri, 26 Aug 2011 22:29:09 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>
		<category><![CDATA[MedcoHealth Solutions Inc.]]></category>
		<category><![CDATA[MHS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82113</guid>
		<description><![CDATA[We recently reiterated our Neutral recommendation on AmerisourceBergen Corporation (ABC) with a target price of $40.00. Over the last several years, the company has been benefiting from the growth of the pharmaceutical industry in the US. We believe AmerisourceBergen should continue to benefit from growth in the pharmaceutical industry, which is driven by several factors like aging population, increased use of generics, introduction of new treatments, increased use of drug therapies and favorable legislative developments. The aforesaid points are continually helping the company, which increased its 2011 earnings guidance range following the release of the third quarter fiscal 2011 financial results. AmerisourceBergen now expects 2011 earnings to lie in the range of $2.52 &#8211; $2.56 per share (previous guidance: $2.41 &#8211; $2.49). We expect fiscal 2011 earnings to increase almost ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/26/abc-amerisourcebergen-analyst-reiterates-neutral-on-shares/82113/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIOS) BioScrip Analyst Maintains Neutral Rating on Shares</title>
		<link>http://www.stockbloghub.com/2011/08/16/bios-bioscrip-analyst-maintains-neutral-rating-on-shares/81415</link>
		<comments>http://www.stockbloghub.com/2011/08/16/bios-bioscrip-analyst-maintains-neutral-rating-on-shares/81415#comments</comments>
		<pubDate>Tue, 16 Aug 2011 16:57:27 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Specialized Health Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[BIOS]]></category>
		<category><![CDATA[BioScrip Inc.]]></category>
		<category><![CDATA[Chico's FAS Inc.]]></category>
		<category><![CDATA[CHS]]></category>
		<category><![CDATA[CVS]]></category>
		<category><![CDATA[CVS Caremark Corporation]]></category>
		<category><![CDATA[MedcoHealth Solutions Inc.]]></category>
		<category><![CDATA[MHS]]></category>
		<category><![CDATA[WAG]]></category>
		<category><![CDATA[Walgreen Company]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=81415</guid>
		<description><![CDATA[We maintain our Neutral recommendation on BioScrip Inc. (BIOS) with a target price of $6.25. BioScrip reported a loss of 4 cents per share in the second quarter of fiscal 2011 compared with the year-ago quarter EPS of 6 cents. However, after deducting the impact of restructuring charges and legal settlement cost, adjusted EPS came in at 10 cents during the quarter, surpassing the Zacks Consensus Estimate of 6 cents. After a few disappointing quarters, impacted by pricing concessions on various specialty drugs, reimbursement pressures, the new industry-wide AWP standard and the overall impact of the weak economic environment, BioScrip is gradually witnessing improvement in its top line. During the second quarter, the company witnessed an 8.7% year-over-year upsidein revenues from its pharmacy services segment, partly offset by the existing ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/16/bios-bioscrip-analyst-maintains-neutral-rating-on-shares/81415/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Third Quarter 2011 Earnings Preview</title>
		<link>http://www.stockbloghub.com/2011/04/27/cah-cardinal-health-third-quarter-2011-earnings-preview/72565</link>
		<comments>http://www.stockbloghub.com/2011/04/27/cah-cardinal-health-third-quarter-2011-earnings-preview/72565#comments</comments>
		<pubDate>Wed, 27 Apr 2011 17:28:55 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health Inc.]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=72565</guid>
		<description><![CDATA[Cardinal Health (CAH) is slated to report its third-quarter fiscal 2011 (ending March) results on Thursday, April 28. The company expects earnings per share in the range of $2.54 to $2.60 for fiscal 2011. The current Zacks Consensus Estimate for revenues and earnings for the third quarter are $25.6 billion and 69 cents per share, respectively. Second Quarter Recap Cardinal Health reported second-quarter fiscal 2011 adjusted earnings per share of 69 cents, beating the Zacks Consensus Estimate of 61 cents and surpassing the year-ago results of 57 cents. Total sales were up 2% year over year to $25.4 billion, beating the Zacks Consensus Estimate. Higher sales from the core Pharmaceutical division were partly offset by a modest decline in the Medical segment. Revenues from the larger Pharmaceutical segment moved up ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/27/cah-cardinal-health-third-quarter-2011-earnings-preview/72565/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WPI) Watson Pharmaceuticals Analyst Maintains Neutral Rating on Shares</title>
		<link>http://www.stockbloghub.com/2011/03/17/wpi-watson-pharmaceuticals-analyst-maintains-neutral-rating-on-shares/68917</link>
		<comments>http://www.stockbloghub.com/2011/03/17/wpi-watson-pharmaceuticals-analyst-maintains-neutral-rating-on-shares/68917#comments</comments>
		<pubDate>Thu, 17 Mar 2011 17:02:54 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health Inc.]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Warner Chilcott Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WCRX]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=68917</guid>
		<description><![CDATA[We recently reaffirmed our Neutral stance on Watson Pharmaceuticals Inc. (WPI) following the release of fourth quarter and fiscal year 2010 financial results. Quarterly earnings of 93 cents per share were in line with the Zacks Consensus Estimate and 8 cents above the year-ago earnings. Revenues increased 21.2% to $952.7 million, mainly due to the strong performance of the generics business. Fourth quarter revenues surpassed the Zacks Consensus Estimate of $921 million. For full year 2010, Watson Pharma earned $3.42 per share (up 12.5%) on revenues of $3.6 billion (up 28%). The Zacks Consensus Estimate for 2010 was $3.42 per share on revenues of $3.5 billion. We believe that the company’s cost saving initiative and new product launches, both branded and generic, will help drive growth. We have raised our ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/03/17/wpi-watson-pharmaceuticals-analyst-maintains-neutral-rating-on-shares/68917/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABC) Publishing Industry Outlook &#8211; February 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/02/18/abc-publishing-industry-outlook-february-2011-industry-outlook/67209</link>
		<comments>http://www.stockbloghub.com/2011/02/18/abc-publishing-industry-outlook-february-2011-industry-outlook/67209#comments</comments>
		<pubDate>Fri, 18 Feb 2011 16:44:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[Gannett Company Inc]]></category>
		<category><![CDATA[GCI]]></category>
		<category><![CDATA[GOOG]]></category>
		<category><![CDATA[Google Inc.]]></category>
		<category><![CDATA[Journal Communications Inc.]]></category>
		<category><![CDATA[JRN]]></category>
		<category><![CDATA[MNI]]></category>
		<category><![CDATA[News Corporation]]></category>
		<category><![CDATA[NWSA]]></category>
		<category><![CDATA[NYT]]></category>
		<category><![CDATA[SSP]]></category>
		<category><![CDATA[The E. W. Scripps Company]]></category>
		<category><![CDATA[The McClatchy Company]]></category>
		<category><![CDATA[The New York Times Company]]></category>
		<category><![CDATA[Washington Post Company]]></category>
		<category><![CDATA[WPO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=67209</guid>
		<description><![CDATA[The publishing industry had long been grappling with sinking advertising revenue, which was exacerbated by the global economic meltdown. This reflected a longer-term secular decline as more readers get news free online, thereby making the print-advertising model increasingly irrelevant. Circulation Falling Prey to the Internet Newspapers have fared far worse than magazines, as web-based news options have proliferated in recent years. The two-decade-long erosion in newspaper circulation reinforced the decline in advertising revenue. Circulation has also fallen prey to budget cuts with newspaper companies reducing the number of print pages and newsroom staff to combat the downturn. However, the recent data available from the Audit Bureau of Circulations (ABC) indicates that the rate of decline in circulation is easing. Newspaper circulation tumbled 5% for the six months ended September 30, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/02/18/abc-publishing-industry-outlook-february-2011-industry-outlook/67209/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BIOS) BioScrip Analyst Reaffirms Shares at Neutral</title>
		<link>http://www.stockbloghub.com/2010/12/27/bios-bioscrip-analyst-reaffirms-shares-at-neutral/63531</link>
		<comments>http://www.stockbloghub.com/2010/12/27/bios-bioscrip-analyst-reaffirms-shares-at-neutral/63531#comments</comments>
		<pubDate>Tue, 28 Dec 2010 00:01:10 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Specialized Health Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[BIOS]]></category>
		<category><![CDATA[BioScrip Inc.]]></category>
		<category><![CDATA[CVS]]></category>
		<category><![CDATA[CVS Caremark Corporation]]></category>
		<category><![CDATA[WAG]]></category>
		<category><![CDATA[Walgreen Company]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=63531</guid>
		<description><![CDATA[We maintain our Neutral recommendation on BioScrip Inc. (BIOS) following its tepid third-quarter fiscal 2010 results. Earnings for the quarter trailed both the Zacks Consensus Estimate and the year-ago earnings. Profit plummeted 66% year over year, hit by higher costs and tax. On a positive note, revenues grew at a healthy double-digit rate, driven by the synergies from the acquisition of Critical Homecare Solutions (“CHS”), a leading provider of infusion therapy products and services. However, organic (excluding the impact of acquisitions) revenue growth was disappointing. BioScrip witnessed softer patient reorder patterns and pricing pressure in some parts of its business, impacting the gross margin for the quarter. Consequent to the disappointing performance in the quarter, the company withdrew its full-year fiscal 2010 guidance and decided to review its business and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/12/27/bios-bioscrip-analyst-reaffirms-shares-at-neutral/63531/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Gets Antitrust Clearance</title>
		<link>http://www.stockbloghub.com/2010/12/20/cah-cardinal-health-gets-antitrust-clearance/62814</link>
		<comments>http://www.stockbloghub.com/2010/12/20/cah-cardinal-health-gets-antitrust-clearance/62814#comments</comments>
		<pubDate>Mon, 20 Dec 2010 20:27:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=62814</guid>
		<description><![CDATA[Cardinal Health (CAH) recently announced that antitrust regulators had cleared its $1.3 billion takeover of Kinray, a leading pharma distributor with a presence in the New York metropolitan area. In this regard, the Federal Trade Commission (“FTC”) had approved early termination of waiting period, under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, for the planned takeover. The cash deal to acquire Kinray will enhance Cardinal’s capability to cater to retail independent pharmacies in the northeastern U.S. markets. Cardinal expects to shortly close the deal. The company earlier anticipated that the transaction will be neutral to slightly accretive to its fiscal 2011 adjusted earnings, contingent upon the time of the deal closure. Cardinal projects accretion of not less than 12 cents in adjusted earning per share from continuing operations in fiscal ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/12/20/cah-cardinal-health-gets-antitrust-clearance/62814/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Announces Buy of Kinray</title>
		<link>http://www.stockbloghub.com/2010/12/19/cah-cardinal-health-announces-buy-of-kinray/60379</link>
		<comments>http://www.stockbloghub.com/2010/12/19/cah-cardinal-health-announces-buy-of-kinray/60379#comments</comments>
		<pubDate>Sun, 19 Dec 2010 23:25:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=60379</guid>
		<description><![CDATA[Cardinal Health (CAH) recently announced plans to purchase Kinray Inc., a leading pharma distributor with a presence in the New York metropolitan area. The cash deal will enhance Cardinal’s capability to cater to retail independent pharmacies in the northeastern U.S. markets. Cardinal expects to close the deal by the end of the current calendar year, or early-2011, depending on regulatory approval and closing conditions. The company anticipates that the transaction will be neutral to slightly accretive to its fiscal 2011 adjusted earnings, contingent upon the time of the deal closure. Cardinal projects accretion of not less than 12 cents in adjusted earning per share from continuing operations in fiscal 2012, after taking into account the effect of amortization of intangibles. Kinray is one of the largest privately held distributors of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/12/19/cah-cardinal-health-announces-buy-of-kinray/60379/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AAPL) Company News For December 14, 2010 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2010/12/14/aapl-company-news-for-december-14-2010-corporate-summary/62272</link>
		<comments>http://www.stockbloghub.com/2010/12/14/aapl-company-news-for-december-14-2010-corporate-summary/62272#comments</comments>
		<pubDate>Tue, 14 Dec 2010 20:34:06 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Personal Computers]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[AAPL]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[Apple Inc.]]></category>
		<category><![CDATA[BP]]></category>
		<category><![CDATA[BP plc]]></category>
		<category><![CDATA[EMC]]></category>
		<category><![CDATA[EMC Corporation]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[Goodrich Corporation]]></category>
		<category><![CDATA[GR]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[JEF]]></category>
		<category><![CDATA[Jefferies Group Inc.]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[SAFM]]></category>
		<category><![CDATA[Sanderson Farms Inc.]]></category>
		<category><![CDATA[TOT]]></category>
		<category><![CDATA[Total SA]]></category>
		<category><![CDATA[Wells Fargo & Company]]></category>
		<category><![CDATA[WFC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=62272</guid>
		<description><![CDATA[• Pfizer (NYSE:PFE) announced a quarterly dividend increase of 11% to $0.20 • Sanderson Farms (NASDAQ:SAFM) reported fiscal fourth quarter earnings of $2.08, beating Zacks Consensus Estimate of $1.69, on revenues of $529.1 million, which was ahead of Zacks Consensus Estimate of $524.0 million • Jefferies (NYSE:JEF) initiated coverage on Total (NYSE:TOT) with a &#8220;buy&#8221; rating and placed British Petroleum (NYSE:BP) at &#8220;hold&#8221; • Goldman Sachs (NYSE:GS) initiated coverage of AmerisourceBergen (NYSE:ABC) and placed the company on its Conviction Buy List • Morgan Stanley (NYSE:MS) removed Apple (NASDAQ:AAPL) from its &#8220;Best Ideas&#8221; List • Janney Montgomery initiated coverage on EMC (NYSE:EMC) with a &#8220;buy&#8221; rating and a target price of $26 • Wells Fargo (NYSE:WFC) upgraded Goodrich (NYSE:GR) to &#8220;outperform&#8221; from &#8220;market perform&#8221; with a target price in the range of $21-$23 • Amgen (NASDAQ:AMGN) announced a study ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/12/14/aapl-company-news-for-december-14-2010-corporate-summary/62272/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABC) Publishing Industry Outlook &#8211; November 2010</title>
		<link>http://www.stockbloghub.com/2010/11/12/abc-publishing-industry-outlook-november-2010/59044</link>
		<comments>http://www.stockbloghub.com/2010/11/12/abc-publishing-industry-outlook-november-2010/59044#comments</comments>
		<pubDate>Fri, 12 Nov 2010 19:38:55 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[Gannett Company Inc]]></category>
		<category><![CDATA[GCI]]></category>
		<category><![CDATA[GOOG]]></category>
		<category><![CDATA[Google Inc.]]></category>
		<category><![CDATA[Journal Communications Inc.]]></category>
		<category><![CDATA[JRN]]></category>
		<category><![CDATA[MNI]]></category>
		<category><![CDATA[News Corporation]]></category>
		<category><![CDATA[NWSA]]></category>
		<category><![CDATA[NYT]]></category>
		<category><![CDATA[SSP]]></category>
		<category><![CDATA[The E. W. Scripps Company]]></category>
		<category><![CDATA[The McClatchy Company]]></category>
		<category><![CDATA[The New York Times Company]]></category>
		<category><![CDATA[Washington Post Company]]></category>
		<category><![CDATA[WPO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=59044</guid>
		<description><![CDATA[The publishing industry has long been grappling with sinking advertising revenue, and the recent global economic meltdown has worsened the situation. This comes in the wake of a longer-term secular decline as more readers choose to get news free online, thereby making the print-advertising model increasingly irrelevant. Circulation Falling Prey to Internet Newspapers have fared far worse than magazines, as web-based news options have proliferated in recent years. The two-decade-long erosion in newspaper circulation reinforced the decline in advertising revenue. Most media observers viewed 2009 as a watershed for the industry. Circulation has also fallen prey to budget cuts with newspaper companies reducing the number of print pages and newsroom staff to combat the downturn. The slide in newspaper circulation, which ran through the 1990s and through the 2000s, is ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/12/abc-publishing-industry-outlook-november-2010/59044/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABC) Company News for November 2, 2010 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2010/11/02/abc-company-news-for-november-2-2010-corporate-summary/57520</link>
		<comments>http://www.stockbloghub.com/2010/11/02/abc-company-news-for-november-2-2010-corporate-summary/57520#comments</comments>
		<pubDate>Wed, 03 Nov 2010 06:26:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[ADM]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[Archer-Daniels-Midland Company]]></category>
		<category><![CDATA[BP]]></category>
		<category><![CDATA[BP plc]]></category>
		<category><![CDATA[Emerson Electric Company]]></category>
		<category><![CDATA[EMR]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[MedcoHealth Solutions Inc.]]></category>
		<category><![CDATA[MHS]]></category>
		<category><![CDATA[NEM]]></category>
		<category><![CDATA[Newmont Mining Corporation]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Tenet Healthcare Corporation]]></category>
		<category><![CDATA[THC]]></category>
		<category><![CDATA[United Parcel Service]]></category>
		<category><![CDATA[UPS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=57520</guid>
		<description><![CDATA[• Pfizer&#8217;s (NYSE:PFE) reported third quarter earnings of $0.54, $0.03 above Zacks estimates as revenues surged 39.2% to $16.2 billion, slightly below Zacks estimates of $16.62 billion • Archer Daniels Midland (NYSE:ADM) posted fiscal first quarter earnings of $0.54, off Zacks estimates of $0.75, on inline revenues of $16.8 billion, up 13% YoY, and beating estimates of $15.52 billion • BP (NYSE:BP) posted better-than-expected results and noted plans to consider reinstating its dividend in 2011. Likely costs for the Macondo oil spill were raised to $40 billion • AmerisourceBergen (NYSE:ABC) topped Zacks estimates by $0.02 with fourth quarter interims of $0.50, on a 5.3% revenue gain to $19.7 billion, above Zacks estimates of $19.4 billion • Medco Health (NYSE:MHS) reported estimate-topping third quarter earnings of $0.91, up from estimates of $0.88, on revenues of $16.32 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/02/abc-company-news-for-november-2-2010-corporate-summary/57520/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Prepares for Coming Flu Season</title>
		<link>http://www.stockbloghub.com/2010/10/03/cah-cardinal-health-prepares-for-coming-flu-season/53709</link>
		<comments>http://www.stockbloghub.com/2010/10/03/cah-cardinal-health-prepares-for-coming-flu-season/53709#comments</comments>
		<pubDate>Mon, 04 Oct 2010 05:13:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=53709</guid>
		<description><![CDATA[Cardinal Health (CAH) is taking necessary steps to maintain the supply of influenza vaccines during the forthcoming 2010-2011 flu season. For the first time, the Advisory Committee on Immunization Practices (ACIP) has been asking everyone over 6 months of age to get a flu vaccine. The company is of the opinion that the supplies are sufficient to meet the demand as a result of which everybody will have access to the vaccine. There is no need of prioritization. The flu season of last year resulted in more than 270,000 hospitalizations and 12,000 deaths. However, the upcoming season should not be very severe due to the immunity developed from the last infection and availability of the flu vaccine. Moreover, the flu vaccine will target the H1N1 strain in addition to the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/03/cah-cardinal-health-prepares-for-coming-flu-season/53709/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Sells Remaining CareFusion Shares</title>
		<link>http://www.stockbloghub.com/2010/09/19/cah-cardinal-health-sells-remaining-carefusion-shares/52054</link>
		<comments>http://www.stockbloghub.com/2010/09/19/cah-cardinal-health-sells-remaining-carefusion-shares/52054#comments</comments>
		<pubDate>Sun, 19 Sep 2010 17:57:49 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=52054</guid>
		<description><![CDATA[Cardinal Health (CAH), a leading distributor of pharmaceuticals and medical supplies, recently sold off the remaining 30.5 million shares of CareFusion Corporation (CFN) for $705.9 million. CareFusion, a San Diego-based vendor for medical equipment and infection control supplies, was spun off from Cardinal Health in 2009. As per the spin-off arrangement, Cardinal Health distributed 0.5 shares of CareFusion common stock for each share of its stock that was outstanding. It retained about 19% of the shares in CareFusion at the time of the distribution. Under the terms of the agreement Cardinal Health was required to dispose of its equity holdings in CareFusion within five years of the distribution (by August 31, 2014). The agreement authorized Cardinal to dispose of its shares through open-market sales, private sales or a combination of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/09/19/cah-cardinal-health-sells-remaining-carefusion-shares/52054/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health and Cumberland Pharmaceuticals Sign Deal</title>
		<link>http://www.stockbloghub.com/2010/08/22/cah-cardinal-health-and-cumberland-pharmaceuticals-sign-deal-2/48444</link>
		<comments>http://www.stockbloghub.com/2010/08/22/cah-cardinal-health-and-cumberland-pharmaceuticals-sign-deal-2/48444#comments</comments>
		<pubDate>Sun, 22 Aug 2010 23:15:27 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[CPIX]]></category>
		<category><![CDATA[Cumberland Pharmaceuticals]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=48444</guid>
		<description><![CDATA[Cardinal Health (CAH), one of the largest distributors of pharmaceuticals and medical supplies, has reportedly inked a distribution agreement with Nashville, Tennessee-based Cumberland Pharmaceuticals (CPIX), a specialty pharmaceutical firm focused on the acute-care hospital and gastroenterology markets. Financial terms of the deal were not divulged by the companies. Under the three-year deal, Cardinal will exclusively distribute three of Cumberland’s drugs in the U.S, Puerto Rico and other specific countries. The drugs covered by the deal are Acetadote, Caldolor and Kristalose. Cumberland will be responsible for delivering these drugs to Cardinal’s distribution center in LaVergne, Tennessee. The deal represents another instance of the long-standing bond between the two companies. Cardinal teamed up with Cumberland in 2002 to market Kristalose (used to treat constipation and hepatic encephalopathy, a brain disorder) in the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/22/cah-cardinal-health-and-cumberland-pharmaceuticals-sign-deal-2/48444/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health and Cumberland Pharmaceuticals Sign Deal</title>
		<link>http://www.stockbloghub.com/2010/08/18/cah-cardinal-health-and-cumberland-pharmaceuticals-sign-deal/48250</link>
		<comments>http://www.stockbloghub.com/2010/08/18/cah-cardinal-health-and-cumberland-pharmaceuticals-sign-deal/48250#comments</comments>
		<pubDate>Wed, 18 Aug 2010 18:32:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[CPIX]]></category>
		<category><![CDATA[Cumberland Pharmaceuticals]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=48250</guid>
		<description><![CDATA[Cardinal Health (CAH), one of the largest distributors of pharmaceuticals and medical supplies, has reportedly inked a distribution agreement with Nashville, Tennessee-based Cumberland Pharmaceuticals (CPIX), a specialty pharmaceutical firm focused on the acute-care hospital and gastroenterology markets. Financial terms of the deal were not divulged by the companies. Under the three-year deal, Cardinal will exclusively distribute three of Cumberland’s drugs in the U.S, Puerto Rico and other specific countries. The drugs covered by the deal are Acetadote, Caldolor and Kristalose. Cumberland will be responsible for delivering these drugs to Cardinal’s distribution center in LaVergne, Tennessee. The deal represents another instance of the long-standing bond between the two companies. Cardinal teamed up with Cumberland in 2002 to market Kristalose (used to treat constipation and hepatic encephalopathy, a brain disorder) in the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/18/cah-cardinal-health-and-cumberland-pharmaceuticals-sign-deal/48250/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Earnings Scorecard</title>
		<link>http://www.stockbloghub.com/2010/08/11/cah-cardinal-health-earnings-scorecard/47655</link>
		<comments>http://www.stockbloghub.com/2010/08/11/cah-cardinal-health-earnings-scorecard/47655#comments</comments>
		<pubDate>Thu, 12 Aug 2010 05:16:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=47655</guid>
		<description><![CDATA[Cardinal Health (CAH), one of the largest distributors of pharmaceuticals and medical supplies, recently reported earnings for fourth-quarter of fiscal year 2010, which beat the Zacks Consensus Estimate by a penny. Revenues grew by a mere 0.5% year over year to $22.3 billion. Pharmaceutical revenues were essentially flat year over year as higher sales to non-bulk customers were offset by lower bulk customer revenues. On a positive note, the company’s generic pharmaceutical business posted a 10% revenue growth in the quarter. The spin-off of CareFusion (CFN) has enabled Cardinal to increase focus on its core healthcare supply chain business. Moreover, Cardinal recently acquired privately held specialty pharmaceutical services company Healthcare Solutions Holding for $667 million. The acquisition has expanded its foothold in the fast-growing specialty pharmaceutical services segment. Agreement – ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/11/cah-cardinal-health-earnings-scorecard/47655/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Analyst Reaffirms Neutral Rating</title>
		<link>http://www.stockbloghub.com/2010/08/10/cah-cardinal-health-analyst-reaffirms-neutral-rating/47468</link>
		<comments>http://www.stockbloghub.com/2010/08/10/cah-cardinal-health-analyst-reaffirms-neutral-rating/47468#comments</comments>
		<pubDate>Wed, 11 Aug 2010 01:34:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=47468</guid>
		<description><![CDATA[We maintain our Neutral recommendation for Cardinal Health (CAH), one of the largest distributors of pharmaceuticals and medical supplies. Earnings for fourth-quarter fiscal 2010 beat the Zacks Consensus Estimate by a penny. However, profit dipped year-over-year, impacted by the spin-off of the company’s non-core Clinical and Medical Products segment (CareFusion), lower customer pricing and supply disruption in the pharmaceutical segment. Revenues grew by a mere 0.5% year-over-year to $22.3 billion, narrowly missing the Zacks Consensus Estimate. Pharmaceutical revenues were essentially flat year-over-year as higher sales to non-bulk customers were offset by lower bulk customer revenues. On a positive note, the company’s generic pharmaceutical business posted a 10% revenue growth in the quarter. Cardinal is one of the largest global healthcare companies that help pharmacies, hospitals and ambulatory care sites to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/10/cah-cardinal-health-analyst-reaffirms-neutral-rating/47468/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Pharma and Biotech Industry Outlook &#8211; July 2010 &#8211; Analyst Interviews</title>
		<link>http://www.stockbloghub.com/2010/07/26/abt-pharma-and-biotech-industry-outlook-july-2010-analyst-interviews/44204</link>
		<comments>http://www.stockbloghub.com/2010/07/26/abt-pharma-and-biotech-industry-outlook-july-2010-analyst-interviews/44204#comments</comments>
		<pubDate>Mon, 26 Jul 2010 14:58:05 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[ABII]]></category>
		<category><![CDATA[Abraxis Bioscience Inc]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=44204</guid>
		<description><![CDATA[The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits (5-8%) through 2014. Over the next five years, products that currently generate more than $142 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Zyprexa. At the same time, new products are not expected to generate the same level of sales as products losing patent protection. With revenue growth stalling or slowing down, companies have been resorting to cost-cutting ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/26/abt-pharma-and-biotech-industry-outlook-july-2010-analyst-interviews/44204/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Pharma and Biotech Industry Outlook &#8211; July 2010 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2010/07/20/abt-pharma-and-biotech-industry-outlook-july-2010-industry-outlook/44146</link>
		<comments>http://www.stockbloghub.com/2010/07/20/abt-pharma-and-biotech-industry-outlook-july-2010-industry-outlook/44146#comments</comments>
		<pubDate>Wed, 21 Jul 2010 03:08:56 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[ABII]]></category>
		<category><![CDATA[Abraxis Bioscience Inc]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=44146</guid>
		<description><![CDATA[The pharmaceutical industry has witnessed major changes over the past few quarters, with performance being affected by factors like sluggish prescription trends, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits (5-8%) through 2014. Over the next five years, products that currently generate more than $142 billion in sales are expected to face generic competition Incorporatedluding Lipitor, Plavix and Zyprexa. At the same time, new products are not expected to generate the same level of sales as products losing patent protection. With revenue growth stalling or slowing down, companies have been resorting to cost-cutting ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/20/abt-pharma-and-biotech-industry-outlook-july-2010-industry-outlook/44146/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABC) Publishing Industry Review and Outlook &#8211; July 2010 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2010/07/06/abc-publishing-industry-review-and-outlook-july-2010-industry-outlook/42643</link>
		<comments>http://www.stockbloghub.com/2010/07/06/abc-publishing-industry-review-and-outlook-july-2010-industry-outlook/42643#comments</comments>
		<pubDate>Tue, 06 Jul 2010 20:46:47 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[Gannett Company Inc]]></category>
		<category><![CDATA[GCI]]></category>
		<category><![CDATA[GOOG]]></category>
		<category><![CDATA[Google Inc.]]></category>
		<category><![CDATA[Journal Communications Inc.]]></category>
		<category><![CDATA[JRN]]></category>
		<category><![CDATA[MNI]]></category>
		<category><![CDATA[News Corporation]]></category>
		<category><![CDATA[NWSA]]></category>
		<category><![CDATA[NYT]]></category>
		<category><![CDATA[SSP]]></category>
		<category><![CDATA[The E. W. Scripps Company]]></category>
		<category><![CDATA[The McClatchy Company]]></category>
		<category><![CDATA[The New York Times Company]]></category>
		<category><![CDATA[Washington Post Company]]></category>
		<category><![CDATA[WPO]]></category>
		<category><![CDATA[Yahoo! Inc.]]></category>
		<category><![CDATA[YHOO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=42643</guid>
		<description><![CDATA[The publishing industry has long been grappling with sinking advertising revenue, and the recent global economic meltdown has worsened the situation. This comes in the wake of a longer-term secular decline as more readers choose to get news free online, thereby making the print-advertising model increasingly irrelevant. Circulation Falling Prey to Internet Newspapers have fared far worse than magazines, as web-based news options have proliferated in recent years. The two-decade-long erosion in newspaper circulation reinforced the decline in advertising revenue. Most media observers viewed 2009 as a watershed for the industry. Circulation has also fallen prey to budget cuts with newspaper companies reducing the number of print pages and newsroom staff to combat the downturn. The slide in newspaper circulation, which ran through the 1990s and through the 2000s, is ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/06/abc-publishing-industry-review-and-outlook-july-2010-industry-outlook/42643/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Quarterly Earnings Outperform</title>
		<link>http://www.stockbloghub.com/2010/04/30/cah-cardinal-health-quarterly-earnings-outperform/35762</link>
		<comments>http://www.stockbloghub.com/2010/04/30/cah-cardinal-health-quarterly-earnings-outperform/35762#comments</comments>
		<pubDate>Fri, 30 Apr 2010 15:52:30 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=35762</guid>
		<description><![CDATA[Cardinal Health, Inc. (CAH) reported third quarter fiscal 2010 earnings per share of 61 cents, outperforming the Zacks Consensus Estimate of 57 cents. However, earnings were lower than the year-ago figure of 66 cents. Sales Total sales in the third quarter increased 1% year over year to $24.3 billion. Growth was witnessed across all business segments. Pharmaceutical segment revenues increased 0.5% year over year to $22.2 billion. Growth was fueled by higher sales to bulk and non-bulk customers. Sales to bulk customers increased 0.5% year over year to $10.9 billion. Sales to non-bulk customers increased 0.5% year over year to $11.3 billion. Medical segment revenues increased 7% year over year to $2.1 billion. Growth can be primarily attributed to higher sales to existing domestic customers and strong performance of the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/30/cah-cardinal-health-quarterly-earnings-outperform/35762/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABC) AmerisourceBergen Beats Forecasts &#8211; Raises Outlook Again</title>
		<link>http://www.stockbloghub.com/2010/04/22/abc-amerisourcebergen-beats-forecasts-raises-outlook-again/34742</link>
		<comments>http://www.stockbloghub.com/2010/04/22/abc-amerisourcebergen-beats-forecasts-raises-outlook-again/34742#comments</comments>
		<pubDate>Thu, 22 Apr 2010 21:32:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=34742</guid>
		<description><![CDATA[AmerisourceBergen Corp. (ABC) posted second quarter fiscal 2010 earnings of 63 cents per share, beating the Zacks Consensus Estimate by 8 cents. Earnings increased 34% from the year-ago period. Performance was driven by strong revenues, successful generic drug launches, and continued expense management. Total revenues for the quarter increased 11.5% to $19.3 billion. This was attributable to a 13% growth in AmerisourceBergen Drug Corp. revenues and a 5% rise in Specialty Group revenues. AmerisourceBergen Drug Corp. revenues were driven by new customer additions and overall market growth. New business accounted for more than 4% of revenue growth. Meanwhile, generic revenues remained strong during the quarter. Gross profit for the second quarter was $612.1 million, which reflected an 11% increase over the year-ago period. The improvement was driven by increased revenue ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/22/abc-amerisourcebergen-beats-forecasts-raises-outlook-again/34742/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABC) Publishing Industry Outlook &#8211; April 2010 &#8211; Stock Review</title>
		<link>http://www.stockbloghub.com/2010/04/01/abc-publishing-industry-outlook-april-2010-stock-review/32518</link>
		<comments>http://www.stockbloghub.com/2010/04/01/abc-publishing-industry-outlook-april-2010-stock-review/32518#comments</comments>
		<pubDate>Thu, 01 Apr 2010 14:55:58 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[Gannett Company Inc]]></category>
		<category><![CDATA[GCI]]></category>
		<category><![CDATA[GOOG]]></category>
		<category><![CDATA[Google Inc.]]></category>
		<category><![CDATA[Journal Communications Inc.]]></category>
		<category><![CDATA[JRN]]></category>
		<category><![CDATA[MNI]]></category>
		<category><![CDATA[News Corporation]]></category>
		<category><![CDATA[NWSA]]></category>
		<category><![CDATA[NYT]]></category>
		<category><![CDATA[SSP]]></category>
		<category><![CDATA[The E. W. Scripps Company]]></category>
		<category><![CDATA[The McClatchy Company]]></category>
		<category><![CDATA[The New York Times Company]]></category>
		<category><![CDATA[Washington Post Company]]></category>
		<category><![CDATA[WPO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=32518</guid>
		<description><![CDATA[The publishing industry has long been grappling with sinking advertising revenue, and the recent global economic meltdown has worsened the situation. This comes in the wake of a longer-term secular decline as more readers choose to get news free online, thereby making the print-advertising model increasingly irrelevant. Circulation Falling Prey to Internet Newspapers have fared far worse than magazines, as web-based news options have proliferated in recent years. The two-decade long erosion in newspaper circulation has reinforced the decline in advertising revenue. Most media observers viewed 2009 as a watershed for the industry, but the picture remains gloomy. The slide in newspaper circulation, which ran through the 1990s and into 2000, is accelerating. Earlier, the circulation of newspaper was falling by less than 1%, but the rate of decline accelerated ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/01/abc-publishing-industry-outlook-april-2010-stock-review/32518/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PBR) U.S. Consumer Price Index Remains Tame</title>
		<link>http://www.stockbloghub.com/2010/03/18/pbr-u-s-consumer-price-index-remains-tame/31205</link>
		<comments>http://www.stockbloghub.com/2010/03/18/pbr-u-s-consumer-price-index-remains-tame/31205#comments</comments>
		<pubDate>Thu, 18 Mar 2010 20:26:45 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Basic Materials]]></category>
		<category><![CDATA[Oil & Gas Drilling & Exploration]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[APA]]></category>
		<category><![CDATA[Apache Corporation]]></category>
		<category><![CDATA[ATP Oil & Gas Corporation]]></category>
		<category><![CDATA[ATPG]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[economy]]></category>
		<category><![CDATA[inflation]]></category>
		<category><![CDATA[PBR]]></category>
		<category><![CDATA[Petroleo Brasileiro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=31205</guid>
		<description><![CDATA[We got more evidence today that inflation is not a serious concern. The Consumer Price Index (CPI) was unchanged in February after five straight months when it had increased by only 0.2% per month. Overall consumer prices are just 2.1% higher than a year ago. If food and energy prices are stripped out to get “core&#8221; inflation, then inflation is also very tame, with core inflation up 0.1% in February, reversing a 0.1% decline in January and a 0.1% increase in December. Over the last year, core inflation has just been 1.3%, and most of that inflation happened earlier in 2009. Actually, food prices have been very well behaved, down 0.2% over the last year, but up slightly (0.1%, 0.2%, and 0.1%) in each of the last three months. Energy ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/18/pbr-u-s-consumer-price-index-remains-tame/31205/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABC) AmerisourceBergen Corporation Reports Robust Quarterly Results</title>
		<link>http://www.stockbloghub.com/2010/02/05/abc-amerisourcebergen-corporation-reports-robust-quarterly-results/27140</link>
		<comments>http://www.stockbloghub.com/2010/02/05/abc-amerisourcebergen-corporation-reports-robust-quarterly-results/27140#comments</comments>
		<pubDate>Sat, 06 Feb 2010 01:26:09 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=27140</guid>
		<description><![CDATA[AmerisourceBergen Corporation (ABC) recently declared a dividend of 8 cents per share. The company pays an industry-leading dividend yield of 1.13%. In late January, the company reported record earnings of 52 cents for the fiscal first quarter, topping the Zacks Consensus Estimate by 13%. Revenue hit a record $19.3 billion, a year-over-year spike of 11.5%. Company Description AmerisourceBergen Corporation, a pharmaceutical services companies serving the United States, Canada and selected global markets, serves both pharmaceutical manufacturers and healthcare providers in the pharmaceutical supply channel. The company distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to various healthcare providers. With more than $70 billion in annual revenue, AmerisourceBergen is headquartered in Valley Forge, PA, and employs approximately 10,000 people. Solid Income The company ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/05/abc-amerisourcebergen-corporation-reports-robust-quarterly-results/27140/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAH) Cardinal Health Beats Expectations and Boosts Estimates</title>
		<link>http://www.stockbloghub.com/2010/01/28/cah-cardinal-health-beats-expectations-and-boosts-estimates/26312</link>
		<comments>http://www.stockbloghub.com/2010/01/28/cah-cardinal-health-beats-expectations-and-boosts-estimates/26312#comments</comments>
		<pubDate>Thu, 28 Jan 2010 20:26:37 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[ESRX]]></category>
		<category><![CDATA[Express Scripts Inc.]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26312</guid>
		<description><![CDATA[Cardinal Health, Inc. (CAH) reported second quarter fiscal 2010 earnings per share of 57 cents, surpassing the Zacks Consensus Estimate of 46 cents and the year-ago earnings of 51 cents. Sales Total sales in the reported quarter increased 3% year over year to $24.9 billion. Growth was witnessed across all business segments. Pharmaceutical segment revenues increased 3% year over year to $22.7 billion. Growth was primarily fueled by higher sales to existing pharmaceutical distribution customers. Sales to bulk customers declined 1% year over year to $11 billion. Sales to non-bulk customers increased 7% year over year to $11.7 billion. Medical segment revenues increased 9% year over year to $2.2 billion. Growth can be primarily attributed to higher sales to existing customers. Margins Gross and operating margins remained unchanged at 3.8% ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/28/cah-cardinal-health-beats-expectations-and-boosts-estimates/26312/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MCK) McKesson Corporation Reports Earnings in Line With Analysts</title>
		<link>http://www.stockbloghub.com/2010/01/27/mck-mckesson-corporation-reports-earnings-in-line-with-analysts/26150</link>
		<comments>http://www.stockbloghub.com/2010/01/27/mck-mckesson-corporation-reports-earnings-in-line-with-analysts/26150#comments</comments>
		<pubDate>Wed, 27 Jan 2010 18:45:06 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26150</guid>
		<description><![CDATA[McKesson Corp. (MCK) reported fiscal third-quarter earnings of $1.19 per share, in line with the Zacks Consensus Estimate. However, earnings increased 13% from the year-ago profit of $1.05. Meanwhile, revenues increased 4% to $28.3 billion, driven by the strong performance of the Distribution Solutions business. The Distribution Solutions segment grew 4% with the U.S. pharmaceutical distribution business, recording a 2% increase in revenues. The loss of two customer buying groups in the U.S. continued to impact the performance of this segment. We believe the performance of the segment will continue to be impacted by lost business through the remainder of the year. Canadian revenues grew 8%, reflecting market growth. Medical-Surgical distribution revenues also increased (up 11%), benefiting from small acquisitions made by the company in late fiscal 2009 and an ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/27/mck-mckesson-corporation-reports-earnings-in-line-with-analysts/26150/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABC) AmerisourceBergen Corporation Surpasses Expectations &#8211; Ups Outlook</title>
		<link>http://www.stockbloghub.com/2010/01/26/abc-amerisourcebergen-corporation-surpasses-expectations-ups-outlook/26050</link>
		<comments>http://www.stockbloghub.com/2010/01/26/abc-amerisourcebergen-corporation-surpasses-expectations-ups-outlook/26050#comments</comments>
		<pubDate>Tue, 26 Jan 2010 22:56:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26050</guid>
		<description><![CDATA[This morning, AmerisourceBergen Corp. (ABC) posted first quarter fiscal 2010 earnings of 52 cents per share, beating the Zacks Consensus Estimate by 6 cents. Earnings increased 44% from the year-ago period. Performance was driven by strong revenues, successful generic drug launches, and continued expense management. Total revenues for the quarter increased 11.5% to $19.3 billion. This was attributable to a 12.9% growth in AmerisourceBergen Drug Corp. revenues and a 7.7% rise in Specialty Group revenues. Generic revenues remained strong during the quarter. Gross profit for the first quarter was $563.4 million, which reflected a 15% increase over the gross profit in the year-ago period. The improvement was driven by increased revenue and new generic pharmaceutical launches, especially in the specialty group. Revenue growth Incorporatedreased gross profit, and expense management helped ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/26/abc-amerisourcebergen-corporation-surpasses-expectations-ups-outlook/26050/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABC) AmerisourceBergen Corp Ups Earnings View</title>
		<link>http://www.stockbloghub.com/2009/12/16/abc-amerisourcebergen-corp-ups-earnings-view/23064</link>
		<comments>http://www.stockbloghub.com/2009/12/16/abc-amerisourcebergen-corp-ups-earnings-view/23064#comments</comments>
		<pubDate>Thu, 17 Dec 2009 05:22:43 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23064</guid>
		<description><![CDATA[AmerisourceBergen Corp. (ABC) increased its earnings expectations for the first quarter of fiscal 2010 and stated that it expects earnings to exceed consensus estimates of 43 cents, mainly due to higher sales of generic drugs. Revenues are expected to grow more than 10% during the quarter. The stock reacted positively to the news, with the share price increasing more than 3%. For fiscal 2010, AmerisourceBergen stated that it expects earnings at the higher end of its previously issued guidance of $1.82 &#8211; $1.92 per share, which represents an increase of 8%-14% over the $1.69 reported by the company in fiscal 2009. The company expects revenue growth in the range of 5% – 7%. Operating margin growth of flat to low single-digit basis points is expected. The company has guided towards ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/16/abc-amerisourcebergen-corp-ups-earnings-view/23064/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABC) AmerisourceBergen Tops Consensus Forecasts</title>
		<link>http://www.stockbloghub.com/2009/11/04/abc-amerisourcebergen-tops-consensus-forecasts/19596</link>
		<comments>http://www.stockbloghub.com/2009/11/04/abc-amerisourcebergen-tops-consensus-forecasts/19596#comments</comments>
		<pubDate>Wed, 04 Nov 2009 23:55:14 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs Wholesale]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=19596</guid>
		<description><![CDATA[AmerisourceBergen Corp. (ABC) posted fourth quarter earnings of 44 cents per share, beating the Zacks Consensus Estimate by 4 cents. Earnings increased 22% from the year-ago period. For the full year, earnings increased 17% to $1.69 per share, 3 cents above the Zacks Consensus Estimate. Performance was driven by strong revenues, lower operating expenses and share repurchases. Total revenues for the quarter increased 9% to $18.7 billion. This was attributable to a 10% growth in AmerisourceBergen Drug Corp. revenues, which was driven primarily by new business and improved market growth and an 8% rise in specialty group sales. Generic revenues remained strong during the quarter, displaying above-market growth. For fiscal 2009, total revenues increased 2% to $71.8 billion. Gross profit for the fourth quarter was $538.5 million, which reflected a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/04/abc-amerisourcebergen-tops-consensus-forecasts/19596/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

